Recurrent mutations in core splicing factors have been reported in several clonal disorders, including cancers. Mutations in SF3B1, a component of the U2 splicing complex, are the most common. SF3B1 ...
A new, multicenter study led by Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering Cancer Center determined how a single mutation in splicing factor 3b subunit 1 (SF3B1), the most ...
Genetic mutations are the spark and fuel for cancer. Hundreds of DNA mutations have been linked to human cancers, and they’re easier than ever to find and catalog, thanks to new genomic technologies.
A new proof-of-concept method reliably engineered a hotspot mutation of SF3B1, a gene-splicing gene, into diverse cancer cell lines, outperforming other contemporary editing approaches. Oncogenesis ...
An international working group of experts in myelodysplastic syndromes proposed the recognition of the SF3B1 variant as a distinct nosologic entity based on the presence of a non-inheritable genetic ...
To identify candidate therapeutic targets for cancers with SF3B1 hotspot mutations, drug-sensitivity screening of an in-house library of 80 small-molecule inhibitors resulted in the identification of ...
When you can’t take down the kingpin, go after his accomplices. This strategy may work for cancer as well, according to scientists at Fred Hutch Cancer Center and Memorial Sloan Kettering Cancer ...
A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying ...
As2S2 restores erythroid maturation in sf3b1-deficient zebrafish by upregulating smad7, revealing a new therapeutic target ...
New research, published in Nature Genetics, shows that more people may benefit from PARP inhibitor drugs, like olaparib, which are already used to treat some breast, ovarian and prostate cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results